Monte Rosa Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 135.35 million compared to USD 108.5 million a year ago. Basic loss per share from continuing operations was USD 2.63 compared to USD 2.3 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.075 USD | +4.64% | -11.63% | -9.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.91% | 245M | |
+23.93% | 44.96B | |
+0.40% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.80% | 26.08B | |
-21.14% | 19.03B | |
+6.86% | 12.75B | |
+29.27% | 12.06B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023